Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: The Swedish TIRA project

Scandinavian Journal of Rheumatology

Volumn 43, Issue 3, 2014, Pages 177-183

  Hallert, E ^a,b   Husberg, M ^a   Kalkan, A ^a   Skogh, T ^b   Bernfort, L ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CAPITAL; DRUG COST; EARLY DIAGNOSIS; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MIDDLE AGED; MULTICENTER STUDY; OUTPATIENT; PENSION; PRIORITY JOURNAL; PRODUCTIVITY; RHEUMATOID ARTHRITIS; SWEDEN; WORK DISABILITY;

ADULT; AGED; AMBULATORY CARE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHYSICAL THERAPY MODALITIES; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SICK LEAVE; SWEDEN; TIME FACTORS;

EID: 84899753575     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.835442     Document Type: Article

References (34)

1. Hallert E, Björk M, Dahlström O, Skogh T, Thyberg I. Disease activity and disability in women and men with early rheumatoid arthritis (RA): An 8-year followup of a Swedish early RA project. Arthritis Care Res 2012;64:1101-7
2. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(Suppl 1):1-12
3. Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA Project). Rheumatology 2004;43:1374-82
4. Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S71-4
5. Franke LC, Ament AJ, van De Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27:S118-23
6. Burmeister GD. RA in 2011: Advances in Diagnosis, treatment and definition of remission. Nature Rev Rheumatol 2012;8:65-6
7. Breedvelt FC,CombeB.Understanding emerging treatment paradigms in rheumatoid artrhritis. Arthritis Res Ther 2011;13(Suppl 1):S3
8. Tak PP, Kalden JR. Advances in rheumatology: New targeted therapeutics. Arthritis Res Ther 2011;13(Suppl 1):S5
9. Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Rapid and sustained health utility gain in anti-Tumour necrosis factor-Treated inflammatory arthritis: Observational data during 7 years in southern Sweden. Ann Rheum Dis 2010;69:352-7
10. Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: A longitudinal observational study. Arthritis Res Ther 2010;12:R35
11. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20
12. Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: A 3-year follow-up (the Swedish TIRA project). Rheumatology 2006 45:325-31
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
14. Prevoo MLL, vant Hof MA, Kuper HH, van Leeuwen MA, van De Putte LBA, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8
15. Svärd A, Kastbom A, Reckner-Olsson A, Skogh T. A comparison between IgG- And IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J Rheumatol 2011;38:1265-72
16. Ekdahl C, Eberhardt KB, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 1988;17:263-71
17. Serden L, Lindquist R, Rosen M. Have DRG-based prospective payment systems influenced the number of secondary diagnoses in health care administrative data?. Health Policy 2003;65:101-17
18. Petersson IF. Team care. Traditions and new trends. J Rheumatol 2006;33:1895-6
19. Zirkzee EJ, Sneep AC, de Buck PD, Allaart CF, Peeters AJ, Ronday HK, et al. Sick leave and work disability in patients with early arthritis. Clin Rheumatol 2008;27:11-19
20. Smolen JS, Han C, van Der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22
21. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti-Tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74
22. Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: Data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12:R42
23. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of antitumor necrosis factor on work disability. J Rheumatol 2007;34:2211-17
24. Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M. Evaluation of the effect of anti-Tumor necrosis factor agent use on rheumatoid arthritis work disability: The jury is still out. Arthritis Rheum 2008;59:1082-9
25. Olofsson T, Englund M, Saxne T, Jöud A, Jacobsson LT, Geborek P, et al. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists a population-based controlled cohort study. Ann Rheum Dis 2010;69:2131-6
26. Neovius M, Simard JF, Askling J; ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?. Ann Rheum Dis 2011;70:1010-15
27. Merkesdal S, Ruof J, Huelsemann JL, Mittendorf T, Handelmann S, Mau W, et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): Comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 2005;53:234-40
28. Eriksson JK, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P, et al. Biological vs conventional combination treatment and work loss in early rheumatoid arthritis: A randomized trial. JAMA Intern Med. Published online: 1 July 2013. doi:10.1001/jamainternmed.2013.7801
29. Hallert E, Husberg M, Bernfort L. The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990-2010: Before and after introduction of biologic agents. Rheumatology 2012;51:338-46
30. Chung CP, Sokka T, Arbogast PG, Pincus T. Work disability in early rheumatoid arthritis: Higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006;65:1653-7
31. Merkesdal S, Ruof J, Schöffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: Composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528-34
32. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996;10:460-6
33. Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, et al. Combination etanercept and methotrexate provides better disease control in very early (4 months) versus early rheumatoid arthritis (4 months and
34. Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30:S72-84.